Keckley Report September 21, 2025
Paul Keckley

The Trump 2.0 administration is 8-months into its MAGA agenda. Summer has passed. Schools are open. Congress is in session. Campaign 2026 is underway. The economy is slowing and public sentiment is dropping.

For U.S. healthcare, it’s more bad news than good. The challenges are unprecedented. Most organizations—hospitals, medical groups, drug and device makers, infomediaries and solution providers, insurers, et al—are defaulting to lower risk bets since the long-term for the health system is unclear.

The good news is that the health system in the U.S. is big, fragmented, complex, expensive (5% CAGR spending increases thru 2034) and slow to change. It is highly regulated at local, state and federal levels, labor intense (20 million) and capital-dependent (government funding, private...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

 
Topics: Biotechnology, Congress / White House, Employer, Govt Agencies, Healthcare System, Insurance, Medical Devices, Patient / Consumer, Pharma, Pharma / Biotech, Provider
Medicare Telehealth, Hospital-at-Home Flexibilities In Danger As Partial Government Shutdown Threat Rises
Federal Discretionary Spending To Address Substance Use Disorders: How Big A Shift?
White House and Congress Turn Focus to Health Policy
CVS accused of shutting out rival pharmacy hubs in House Judiciary investigation
OIG Recounts Historic Recovery Numbers in Its Latest Semiannual Report to Congress

Share Article